NEPH — Nephros, Inc.

Nephros Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $4.7 million, a 22% increase year-over-year.
• Full Year 2025 Revenue: $18.8 million, up 33% from $14.2 million in 2024.
• Net Income: $1.2 million for the full year, compared to $0.1 million in 2024; Q4 net income was $0.1 million, down from $0.3 million in Q4 2024.
• Gross Margin: 62% for the full year; Q4 gross margin was 58%, down from 64% in Q4 2024, affected by tariffs.
• Adjusted EBITDA: $1.6 million for the full year; Q4 adjusted EBITDA was $131,000, down from $481,000 in Q4 2024.
• Cash Position: $5.4 million at year-end, up from $3.8 million a year prior, with no debt.

2. Strategic Updates and Business Highlights

• Nephros is focusing on three core pillars: Products, Services, and Education.
  • Products: Advanced filtration technologies for water safety, expanding into non-patient care applications (e.g., ice machines, drinking fountains).
  • Services: Enhanced installation and replacement capabilities to support recurring revenue and customer relationships.
  • Education: Launched the Nephros Water Institute to raise awareness about water safety, engaging over 1,000 participants through webinars and training sessions.
• Active customer sites increased to approximately 1,680 by year-end, reflecting strong customer retention and outreach efforts.

3. Forward Guidance and Outlook

• Nephros is optimistic about growth opportunities in non-medical markets, including hospitality and commercial sectors.
• The company anticipates that education and improved service offerings will drive demand in these new verticals over the coming years.
• Management views the growing awareness of waterborne pathogens and regulatory pressures as favorable trends for their business.

4. Bad News, Challenges, or Points of Concern

• Declining Gross Margins: Margins decreased in the second half of 2025 due to tariffs on imported goods from Italy, creating uncertainty regarding future margin impacts.
• Increased Expenses: R&D and SG&A expenses rose significantly, impacting net income in Q4.
• Tariff Risks: The company remains exposed to unpredictable U.S. tariff policies, which could affect future profitability.

5. Notable Q&A Insights

• Programmatic Sales: Represented over 90% of total revenue for both Q4 and the full year, with strong growth in active customer sites attributed to customer referrals and retention efforts.
• Market Expansion: Management emphasized that while the company has made strides in non-patient care markets, building awareness and overcoming installation complexities will require a multi-year strategy.
• Success Stories: Notable successes include penetration into correctional facilities, schools, and aviation sectors, highlighting the versatility of their filtration solutions beyond healthcare.

Overall, Nephros demonstrated strong financial growth in 2025, with strategic initiatives aimed at expanding market reach and enhancing customer relationships, despite facing challenges related to tariffs and rising operational costs.